Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Acta Neuropathologica Communications
Published in: Acta Neuropathologica Communications 1/2013

Open Access 01-12-2013 | Research

Differential expression of neuregulin-1 isoforms and downregulation of erbin are associated with Erb B2 receptor activation in diabetic peripheral neuropathy

Authors: Pan Pan, Rick T Dobrowsky

Published in: Acta Neuropathologica Communications | Issue 1/2013

Login to get access

Abstract

Background

Aberrant neuron/glia interactions can contribute to a variety of neurodegenerative diseases and we have previously demonstrated that enhanced activation of Erb B2, which is a member of the epidermal growth factor receptor (EGFR) family, can contribute to the development of diabetic peripheral neuropathy (DPN). In peripheral nerves, Erb B receptors are activated by various members of the neuregulin-1 (NRG1) family including NRG1 Type I, NRG1 Type II and NRG1 Type III to regulate Schwann cell (SC) growth, migration, differentiation and dedifferentiation. Alternatively, Erb B2 activity can be negatively regulated by association with the Erb B2-interacting protein, erbin. Since the effect of diabetes on the expression of NRG1 isoforms and erbin in peripheral nerve are unknown, the current study determined whether changes in NRG1 isoforms and erbin may be associated with altered Erb B2 signaling in DPN.

Results

Swiss Webster mice were rendered diabetic with streptozotocin (STZ) and after 12 weeks of diabetes, treated with erlotinib, an inhibitor of Erb B2 activation. Inhibition of Erb B2 signaling partially reversed several pathophysiologic aspects of DPN including a pronounced sensory hypoalgesia, nerve conduction velocity deficits and the decrease in epidermal nerve fiber innervation. We also observed a decrease of NRG1 Type III but an increase of NRG1 Type I level in diabetic sural nerves at early stage of diabetes. With disease progression, we detected reduced erbin expression and enhanced MAPK pathway activity in diabetic mice. Inhibition of Erb B2 receptor suppressed MAPK pathway activity in treated-diabetic sural nerves.

Conclusions

These results support that hyperglycemia may impair NRG1/Erb B2 signaling by disrupting the balance between NRG1 isoforms, decreasing the expression of erbin and correspondingly activating the MAPK pathway. Together, imbalanced NRG1 isoforms and downregulated erbin may contribute to the dysregulation of Erb B2 signaling in the development of DPN.
Appendix
Available only for authorised users
Literature
1.
Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL: Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol 2012, 11: 521–534.PubMedCentralCrossRefPubMed
2.
Zochodne DW: Diabetes mellitus and the peripheral nervous system: manifestations and mechanisms. Muscle Nerve 2007, 36: 144–166.CrossRefPubMed
3.
Sinnreich M, Taylor BV, Dyck PJ: Diabetic neuropathies. Classification, clinical features, and pathophysiological basis. Neurologist 2005, 11: 63–79.CrossRefPubMed
4.
Obrosova IG: Diabetes and the peripheral nerve. Biochim Biophys Acta 2009, 10: 931–940.CrossRef
5.
Calcutt NA, Jolivalt CG, Fernyhough P: Growth factors as therapeutics for diabetic neuropathy. Curr Drug Targets 2008, 9: 47–59.CrossRefPubMed
6.
Leinninger GM, Feldman EL: Insulin-like growth factors in the treatment of neurological disease. Endocrine Dev 2005, 9: 135–159.CrossRef
7.
Liu X, Bates R, Yin DM, Shen C, Wang F, Su N, Kirov SA, Luo Y, Wang JZ, Xiong WC, Mei L: Specific regulation of NRG1 isoform expression by neuronal activity. J Neurosci 2011, 31: 8491–8501.PubMedCentralCrossRefPubMed
8.
Esper RM, Pankonin MS, Loeb JA: Neuregulins: Versatile growth and differentiation factors in nervous system development and human disease. Brain Res Brain Res Rev 2006, 51: 161–175.CrossRef
9.
Grinspan JB, Marchionni MA, Reeves M, Coulaloglou M, Scherer SS: Axonal interactions regulate Schwann cell apoptosis in developing peripheral nerve: neuregulin receptors and the role of neuregulins. J Neurosci 1996, 16: 6107–6118.PubMed
10.
Nave KA, Salzer JL: Axonal regulation of myelination by neuregulin 1. Curr Opin Neurobiol 2006, 16: 492–500.CrossRefPubMed
11.
Taveggia C, Zanazzi G, Petrylak A, Yano H, Rosenbluth J, Einheber S, Xu X, Esper RM, Loeb JA, Shrager P, Chao MV, Falls DL, Role L, Salzer JL: Neuregulin-1 type III determines the ensheathment fate of axons. Neuron 2005, 47: 681–694.PubMedCentralCrossRefPubMed
12.
Michailov GV, Sereda MW, Brinkmann BG, Fischer TM, Haug B, Birchmeier C, Role L, Lai C, Schwab MH, Nave KA: Axonal neuregulin-1 regulates myelin sheath thickness. Science 2004, 304: 700–703.CrossRefPubMed
13.
Chen S, Velardez MO, Warot X, Yu Z-X, Miller SJ, Cros D, Corfas G: Neuregulin 1-ErbB signaling is necessary for normal myelination and sensory function. J Neurosci 2006, 26: 3079–3086.CrossRefPubMed
14.
Chen S, Rio C, Ji RR, Dikkes P, Coggeshall RE, Woolf CJ, Corfas G: Disruption of ErbB receptor signaling in adult non-myelinating Schwann cells causes progressive sensory loss. Nat Neurosci 2003, 6: 1186–1193.CrossRefPubMed
15.
Guertin AD, Zhang DP, Mak KS, Alberta JA, Kim HA: Microanatomy of axon/glial signaling during Wallerian degeneration. J Neurosci 2005, 25: 3478–3487.CrossRefPubMed
16.
Zanazzi G, Einheber S, Westreich R, Hannocks MJ, Bedell-Hogan D, Marchionni MA, Salzer JL: Glial growth factor/neuregulin inhibits Schwann cell myelination and induces demyelination. J Cell Biol 2001, 152: 1289–1299.PubMedCentralCrossRefPubMed
17.
Syed N, Reddy K, Yang DP, Taveggia C, Salzer JL, Maurel P, Kim HA: Soluble neuregulin-1 has bifunctional, concentration-dependent effects on schwann cell myelination. J Neurosci 2010, 30: 6122–6131.PubMedCentralCrossRefPubMed
18.
Napoli I, Noon Luke A, Ribeiro S, Kerai Ajay P, Parrinello S, Rosenberg Laura H, Collins Melissa J, Harrisingh Marie C, White Ian J, Woodhoo A, Lloyd Alison C: A central role for the ERK-signaling pathway in controlling Schwann cell plasticity and peripheral nerve regeneration in vivo. Neuron 2012, 73: 729–742.CrossRefPubMed
19.
Borg JP, Marchetto S, Le Bivic A, Ollendorff V, Jaulin-Bastard F, Saito H, Fournier E, Adelaide J, Margolis B, Birnbaum D: ERBIN: a basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor. Nat Cell Biol 2000, 2: 407–414.CrossRefPubMed
20.
21.
McGuire JF, Rouen S, Siegfreid E, Wright DE, Dobrowsky RT: Caveolin-1 and altered neuregulin signaling contribute to the pathophysiological progression of diabetic peripheral neuropathy. Diabetes 2009, 58: 2677–2686.PubMedCentralCrossRefPubMed
22.
Kennedy JM, Zochodne DW: Experimental diabetic neuropathy with spontaneous recovery: is there irreparable damage? Diabetes 2005, 54: 830–837.CrossRefPubMed
23.
Malik RA, Veves A, Tesfaye S, Smith G, Cameron N, Zochodne D, Lauria G, on behalf of The Toronto Consensus Panel on Diabetic N: Small fibre neuropathy: role in the diagnosis of diabetic sensorimotor polyneuropathy. Diab Metab Res Rev 2011, 27: 678–684.CrossRef
24.
Johnson MS, Ryals JM, Wright DE: Early loss of peptidergic intraepidermal nerve fibers in an STZ-induced mouse model of insensate diabetic neuropathy. Pain 2008, 140: 35–47.PubMedCentralCrossRefPubMed
25.
Beiswenger KK, Calcutt NA, Mizisin AP: Dissociation of thermal hypoalgesia and epidermal denervation in streptozotocin-diabetic mice. Neurosci Lett 2008, 442: 267–272.PubMedCentralCrossRefPubMed
26.
Urban MJ, Pan P, Farmer KL, Zhao H, Blagg BS, Dobrowsky RT: Modulating molecular chaperones improves sensory fiber recovery and mitochondrial function in diabetic peripheral neuropathy. Exp Neurol 2012, 235: 388–396.PubMedCentralCrossRefPubMed
27.
Wang JY, Miller SJ, Falls DL: The N-terminal region of neuregulin isoforms determines the accumulation of cell surface and released neuregulin ectodomain. J Biol Chem 2001, 276: 2841–2851.CrossRefPubMed
28.
Huang YZ, Zang M, Xiong WC, Luo Z, Mei L: Erbin suppresses the MAP kinase pathway. J Biol Chem 2003, 278: 1108–1114.CrossRefPubMed
29.
Hinder LM, Vivekanandan-Giri A, McLean LL, Pennathur S, Feldman EL: Decreased glycolytic and tricarboxylic acid cycle intermediates coincide with peripheral nervous system oxidative stress in a murine model of type 2 diabetes. J Endocrinol 2013, 216: 1–11.PubMedCentralCrossRefPubMed
30.
Fleck D, Garratt AN, Haass C, Willem M: BACE1 dependent neuregulin processing: review. Curr Alzheimer Res 2012, 9: 178–183.CrossRefPubMed
31.
La Marca R, Cerri F, Horiuchi K, Bachi A, Feltri ML, Wrabetz L, Blobel CP, Quattrini A, Salzer JL, Taveggia C: TACE (ADAM17) inhibits Schwann cell myelination. Nat Neurosci 2011, 14: 857–865.CrossRefPubMed
32.
Velanac V, Unterbarnscheidt T, Hinrichs W, Gummert MN, Fischer TM, Rossner MJ, Trimarco A, Brivio V, Taveggia C, Willem M, Haass C, Möbius W, Nave K-A, Schwab MH: Bace1 processing of NRG1 type III produces a myelin-inducing signal but is not essential for the stimulation of myelination. Glia 2012, 60: 203–217.PubMedCentralCrossRefPubMed
33.
34.
Davies KP, Zhao W, Tar M, Figueroa JC, Desai P, Verselis VK, Kronengold J, Wang H-Z, Melman A, Christ GJ: Diabetes-induced changes in the alternative splicing of the Slo gene in corporal tissue. Eur Urol 2007, 52: 1229–1237.PubMedCentralCrossRefPubMed
35.
Gui C, Zhu L, Hu M, Lei L, Long Q: Neuregulin-1/ErbB signaling is impaired in the rat model of diabetic cardiomyopathy. Cardiovasc Path 2012, 21: 414–420.CrossRef
36.
Odiete O, Konik EA, Sawyer DB, Hill MF: Type 1 diabetes mellitus abrogates compensatory augmentation of myocardial neuregulin-1beta/ErbB in response to myocardial infarction resulting in worsening heart failure. Cardiovasc Diabetol 2013, 12: 52.PubMedCentralCrossRefPubMed
37.
Mizisin AP, DiStefano PS, Liu X, Garrett DN, Tonra JR: Decreased accumulation of endogenous brain-derived neurotrophic factor against constricting sciatic nerve ligatures in streptozotocin-diabetic and galactose-fed rats. Neurosci Lett 1999, 263: 149–152.CrossRefPubMed
38.
Mizisin AP, Bache M, DiStefano PS, Acheson A, Lindsay RM, Calcutt NA: BDNF attenuates functional and structural disorders in nerves of galactose-fed rats. J Neuropathol Exp Neurol 1997, 56: 1290–1301.CrossRefPubMed
39.
Ma Z, Wang J, Song F, Loeb JA: Critical period of axoglial signaling between neuregulin-1 and brain-derived neurotrophic factor required for early Schwann cell survival and differentiation. J Neurosci 2011, 31: 9630–9640.PubMedCentralCrossRefPubMed
40.
Stassart RM, Fledrich R, Velanac V, Brinkmann BG, Schwab MH, Meijer D, Sereda MW, Nave KA: A role for Schwann cell-derived neuregulin-1 in remyelination. Nat Neurosci 2013, 16: 48–54.CrossRefPubMed
41.
Liang C, Tao Y, Shen C, Tan Z, Xiong WC, Mei L: Erbin is required for myelination in regenerated axons after injury. J Neurosci 2012, 32: 15169–15180.PubMedCentralCrossRefPubMed
42.
Rangwala R, Banine F, Borg JP, Sherman LS: Erbin regulates mitogen-activated protein (MAP) kinase activation and MAP kinase-dependent interactions between merlin and adherens junction protein complexes in Schwann cells. J Biol Chem 2005, 280: 11790–11797.CrossRefPubMed
43.
Harrisingh MC, Perez-Nadales E, Parkinson DB, Malcolm DS, Mudge AW, Lloyd AC: The Ras/Raf/ERK signalling pathway drives Schwann cell dedifferentiation. EMBO J 2004, 23: 3061–3071.PubMedCentralCrossRefPubMed
44.
Purves TD, Middlemas A, Agthong SI, Jude EB, Boulton AJM, Fernyhough P, Tomlinson DR: A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy. FASEB J 2001, 15: 2508–2514.CrossRefPubMed
Metadata
Title
Differential expression of neuregulin-1 isoforms and downregulation of erbin are associated with Erb B2 receptor activation in diabetic peripheral neuropathy
Authors
Pan Pan
Rick T Dobrowsky
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Acta Neuropathologica Communications / Issue 1/2013
Electronic ISSN: 2051-5960
DOI
https://doi.org/10.1186/2051-5960-1-39

Other articles of this Issue 1/2013

Acta Neuropathologica Communications 1/2013 Go to the issue

Research

Human fetal inner ear involvement in congenital cytomegalovirus infection

Research

Cerebellar hemorrhagic injury in premature infants occurs during a vulnerable developmental period and is associated with wider neuropathology

Research

MCP-1/CCR2 signaling-mediated astrocytosis is accelerated in a transgenic mouse model of SOD1-mutated familial ALS

Research

Alcohol-induced apoptosis of oligodendrocytes in the fetal macaque brain

Research

RETRACTED ARTICLE: Decreased neuroinflammation and increased brain energy homeostasis following environmental enrichment after mild traumatic brain injury is associated with improvement in cognitive function

Research

The type of Aβ-related neuronal degeneration differs between amyloid precursor protein (APP23) and amyloid β-peptide (APP48) transgenic mice